医疗设备制造商IRTC(Irhythm Technologies Inc.)今日盘中大涨5.3%,引发市场广泛关注。
消息显示,分析师普遍对公司未来发展前景持乐观态度。知名券商Needham将IRTC的目标股价从96美元上调至112美元,继续给予"买入"评级。该行预计IRTC今年第四季度营收将超过1.6亿美元,预计为1.575亿美元,主要得益于公司心脏监测设备Zio monitor和Zio AT的销售推动。分析师还预计,该公司2025年收入在6.75亿至6.85亿美元区间,并将进一步提高盈利能力。
综合来看,IRTC股价本日大涨或与分析师普遍看好公司前景、上调目标股价有关。该公司通过创新产品赢得市场认可,在心脏监测领域拥有较强竞争力。市场预期其业绩持续向好,成为股价上涨重要利好因素之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.